These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33034902)

  • 21. Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Ishdorj G; Nugent Z; Squires M; Kost S; Banerji V; Davidson L; Katyal CS; Marshall A; Gibson SB; Johnston JB
    Leuk Res; 2021 Oct; 109():106628. PubMed ID: 34134067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Vigna E; Martino EA; Mendicino F; Botta C; Caracciolo D; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Am J Hematol; 2021 May; 96(5):E168-E171. PubMed ID: 33580969
    [No Abstract]   [Full Text] [Related]  

  • 24. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
    Reda G; Cassin R; Gentile M; Mauro FR; Giannarelli D; Fattizzo B; Barbieri M; Silvestris I; Fabris S; Morabito F; Neri A; Barcellini W; Cortelezzi A
    Leukemia; 2019 Jun; 33(6):1519-1522. PubMed ID: 30635629
    [No Abstract]   [Full Text] [Related]  

  • 25. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 26. [Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia].
    Sakata M; Saburi M; Kawano K; Takata H; Miyazaki Y; Uchida H; Kawano Y; Ohtsuka E
    Rinsho Ketsueki; 2021; 62(3):196-199. PubMed ID: 33828015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    Steingrímsson V; Gíslason GK; Þorsteinsdóttir S; Rögnvaldsson S; Gottfreðsson M; Aspelund T; Turesson I; Björkholm M; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Mar; 106(3):346-353. PubMed ID: 33211356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
    Frei M; Aitken SL; Jain N; Thompson P; Wierda W; Kontoyiannis DP; DiPippo AJ
    Leuk Lymphoma; 2020 Oct; 61(10):2488-2491. PubMed ID: 32530347
    [No Abstract]   [Full Text] [Related]  

  • 29. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
    Lujan JV; Lengerke-Diaz PA; Jacobs C; Moreno-Cortes EF; Ramirez-Segura CA; Choi MY; McCarthy C; Heinen A; Kipps TJ; Castro JE
    Haematologica; 2020 Jan; 105(1):e22-e25. PubMed ID: 31048356
    [No Abstract]   [Full Text] [Related]  

  • 30. Enterobius vermicularis Infection of the Lung Associated With the Use of Ibrutinib in a Patient With Chronic Lymphocytic Leukemia.
    Mousavi-Fatemi K; Mousavi SA; Khosravi S; Maleki N
    Am J Ther; 2020 Oct; 28(6):e801-e803. PubMed ID: 33065571
    [No Abstract]   [Full Text] [Related]  

  • 31. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
    Fiorcari S; Atene CG; Maffei R; Debbia G; Potenza L; Luppi M; Marasca R
    Haematologica; 2021 Aug; 106(8):2265-2268. PubMed ID: 33691383
    [No Abstract]   [Full Text] [Related]  

  • 32. Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    AlHaj Issa Z; Altwijri A; Alfayez M
    Br J Haematol; 2022 Aug; 198(3):414. PubMed ID: 35499126
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
    Hampel PJ; Cherng HJ; Call TG; Ding W; Khanlari M; McPhail ED; Miranda RN; Lin P; Tawbi HA; Ferrajoli A; Wierda WG; Jain N; Parikh SA
    Blood Adv; 2020 Sep; 4(18):4508-4511. PubMed ID: 32946567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
    Molica S; Lentini M; Zappalà D; Levato L
    Leuk Lymphoma; 2020 Nov; 61(11):2778-2780. PubMed ID: 32543252
    [No Abstract]   [Full Text] [Related]  

  • 35. Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Hansenne A; Camboni A; Van Den Neste E; Bailly S
    Leuk Lymphoma; 2021 Dec; 62(12):3051-3053. PubMed ID: 34429010
    [No Abstract]   [Full Text] [Related]  

  • 36. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
    Sigmund AM; Huang Y; Ruppert AS; Maddocks K; Rogers KA; Jaglowski S; Bhat SA; Kittai AS; Grever MR; Byrd JC; Woyach JA
    Leukemia; 2022 Aug; 36(8):2129-2131. PubMed ID: 35842461
    [No Abstract]   [Full Text] [Related]  

  • 40. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.